HMGN1P30: A Drug Target / Disease Biomarker (G100132992)

Target Name: HMGN1P30

NCBI ID: G100132992

HMGN1P30

Other Name(s): high mobility group nucleosome binding domain 1 pseudogene 30 | High mobility group nucleosome binding domain 1 pseudogene 30

HMGN1P30: A Drug Target / Disease Biomarker

HMGN1P30, also known as human mucin 1 protein-30, is a gene that encodes a protein that is expressed in various tissues throughout the body. The protein is made up of 30 amino acids and has a calculated molecular weight of 3.1 kDa. It is a cell surface glycoprotein that is involved in several physiological processes in the body, including cell adhesion, migration, and signaling.

HMGN1P30 has been identified as a potential drug target and has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to its potential as a therapeutic agent for the treatment of a range of conditions.

One of the key challenges in studying HMGN1P30 is its expression and function. While it is widely expressed in many different tissues, its exact localization and function remain poorly understood. Researchers have identified that HMGN1P30 is expressed in various tissues, including the brain, heart, liver, and pancreas, and has been shown to localize to the endoplasmic reticulum (ER) and to play a role in the ER-to-cellular membrane transport system.

Additionally, the role of HMGN1P30 in cell signaling and signaling pathways is not well understood. While it has been shown to be involved in several signaling pathways, including the TGF-β pathway, it is not clear how these signaling pathways are involved in the regulation of cellular processes.

Despite these challenges, researchers have made significant progress in the study of HMGN1P30. They have identified that the protein is involved in several cellular processes, including cell adhesion, migration, and signaling. They have also shown that the protein can interact with several other proteins and has been shown to play a role in the regulation of cellular processes, including cell signaling and the regulation of gene expression.

In addition to its potential role as a drug target, HMGN1P30 also has potential as a biomarker for several diseases. Its expression has been shown to be associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, its expression has been shown to be regulated by several factors, including DNA methylation and histone modification.

Overall, HMGN1P30 is a promising protein for the development of new therapeutic agents for a range of diseases. Further research is needed to fully understand its role in cellular processes and its potential as a drug or biomarker.

Protein Name: High Mobility Group Nucleosome Binding Domain 1 Pseudogene 30

The "HMGN1P30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN1P30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets